A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors (SUMMIT-1)
A Phase 1 Investigation of the Safety, Tolerability and Preliminary Antitumor Activity of BPT567, a Multifunctional PD1-IL18 Immunocytokine in Patients With Advanced Solid Tumors
Sponsor: Bright Peak Therapeutics Inc
Terminated
Sponsor decision
A observational or N/A phase clinical study on Advanced Solid Tumors, this trial is terminated or withdrawn. The trial is conducted by Bright Peak Therapeutics Inc and has accumulated 5 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Apr 23, 2026 — Present [daily]
Terminated
Status: Active Not Recruiting → Terminated · Phase: PHASE1 → None
-
Feb 2026 — Apr 2026 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Dec 2025 — Feb 2026 [monthly]
Recruiting PHASE1
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE1
-
Feb 2025 — Nov 2025 [monthly]
Recruiting PHASE1
First recorded
Oct 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and maximum tolerated dose (MTD) or maximum adminstered dose (MAD) of BPT567 in patients with advanced solid tumors, and establish the recommended dose for expansion cohorts.
Contact Information
- Bright Peak Therapeutics Inc
For direct contact, visit the study record on ClinicalTrials.gov .